Global Cancer mTOR Inhibitors Market & Clinical Pipeline Outlook 2022

  • ID: 4459681
  • Report
  • Region: Global
  • 160 Pages
  • Kuick Research
1 of 5

FEATURED COMPANIES

  • Abraxis BioScience
  • Celator Pharmaceuticals
  • Eli Lilly
  • GlaxoSmithKline
  • Intellikine
  • Oneness Biotech
  • MORE

“Global Cancer mTOR Inhibitors Market & Clinical Pipeline Outlook 2022” gives comprehensive insight on the clinical and non-clinical parameters related to the emergence and development of role of mTOR inhibitors in the cancer therapy.  Report highlights the clinical development of more than 25 cancer tubulin inhibitors drugs in pipeline and shares in-depth dosage/price analysis of more than 10 cancer mTOR inhibitors drugs commercially available and approved in the market.

“Global Cancer mTOR Inhibitors Market & Clinical Pipeline Outlook 2022” Report highlights:

  • Clinical Insight: 27 mTOR Inhibitors in Pipeline
  • Commercially Avaliable: 2 mTOR Inhibitors
  • Working Mechanism of mTOR Inhibitors in Cancer Therapy
  • Clinical Status & Application of mTOR inhibitors in Various Types of Cancer
  • Global Demand & Opportunities in the mTOR Inhibitor Market

Mammalian target of rapamycin (mTOR) is an interesting target as this protein is involved in the regulation of various important cellular processes. Additionally, mTOR is a major component which is receives external signals from external signals via hormones, proteins, growth factors and generate on or off signals to induce cell growth and cell division. Moreover, mTOR proteins are considered as a member of various other vital cellular pathways such as PI3K and AKT.

Although Inhibitors for PI3K and AKT are already developed and commercialized for treating cancer but mTOR Inhibitors have proven to be better than these two classes of anti-cancer therapeutics. Furthermore, mutations in mTOR are more commonly found in lung cancer, breast cancer, colon cancer, ovarian cancer and cervical cancer. Such research findings indicating a huge patient base for mTOR inhibitors led to the development of a successful global mTOR Inhibitor cancer therapy market.  

An insight into the current status of oncology market shows the dominance of North America in almost all the cancer therapeutic segment including the mTOR inhibitor market. The presence of cutting edge technology, excellent human resource in the form of professional researchers and scientist and acceptance of novel therapeutics have been the leading factors in the progress of the mTOR inhibitors market.

The approval of everolimus led to the quick entrance of everolimus into the mTOR inhibitor market which played an important role in giving the mTOR inhibitor market a good start. Novartis has succeeded in establishing the mTOR inhibitor market presence in nations like Europe and Australia which has had a positive impact on the overall growth of the mTOR inhibitor therapy market.

Furthermore, Asian region has been found to be the most promising area for mTOR inhibitor cancer therapy market due to high prevalence leading to high consumer base creating great opportunities for the market. Moreover, large number of pharmaceutical companies and biotechnology research firms present in Asian countries like India, China and Japan are indulged in developing unique mTOR inhibitors which will fuel the market growth in these regions. Additionally, Asian market will be enhanced due to extensive escalation in the healthcare sector with increased healthcare facilities.

Our analysis shows that North America is likely to remain the dominant mTOR inhibitor market in the future with increasing prevalence of cancer, research and development for the improvement of currently existing therapeutics and most importantly, the presence of a strong clinical pipeline.

The mTOR inhibitor market will soon be flourished by more than 10 new products which are in the later phases of clinical trials. Additionally, a wide range of products in the early phases have been showing promising results. Global mTOR inhibitor market is expected to acquire a wider range of consumer base as the products in the clinical pipeline are indicated for malignancies including hematological malignancies and solid tumors other than lung, breast, cervical, colon and ovarian cancer.

READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Abraxis BioScience
  • Celator Pharmaceuticals
  • Eli Lilly
  • GlaxoSmithKline
  • Intellikine
  • Oneness Biotech
  • MORE

1. Mammalian Target of Rapamycin Inhibitors (mTOR) - The Future of Cancer Growth Blockers
1.1 Preliminary Insight to mTOR Inhibitors
1.2 History & Evolution of the mTOR Inhibitors

2. mTOR Signalling Pathway: Their Role & Significance in Cancer
2.1 mTOR Signalling: A Vital Function in Cell Growth
2.2 mTOR Signalling Pathway & Tumorigenesis

3. Principles of mTOR inhibitors in Cancer Therapy
3.1 Activation of mTOR/pI3K pathway in Cancer
3.2 Potential of mTOR as a Targeted Therapy
3.3 Global - Cancer MTOR Inhibitors Clinical Pipeline Overview

4. Working Mechanism of mTOR Inhibitors in Cancer Therapy
4.1 Effect of mTOR inhibitors in Cancer Cells
4.2 Effects of mTOR inhibitors on Tumor Angiogenesis

5. Clinical Status & Application of mTOR inhibitors in Various Types of Cancer
5.1 Breast Cancer
5.1.1 HER2-Positive Breast Cancer
5.1.2 HER-2 Negative Breast Cancer
5.2 Hematological Malignancy
5.2.1 Acute Myeloid Leukemia
5.2.2 Chronic Myelogenous Leukemia
5.2.3 Acute Lymphoblastic Leukemia
5.2.4 Multiple Myeloma
5.2.5 Lymphoma
5.3 Neuroendocrine Tumors
5.4 Hepatocellular Carcinoma
5.5 Glioblastoma (Brain Tumor)
5.6 Other Cancers/Tumors Where mTOR Inhibitors Could be Effective
5.6.1 Non-small Cell Lung Cancers
5.6.2 Colon Cancer

6. Recent Advances in mTOR Inhibitor Cancer Therapy
6.1 Drug Combinations as a Therapeutic Approach for mTORC1 Inhibitors in Human Cancer
6.2 Optimizing Activity of Rapalogs Using Combinations with Other Anticancer Drugs

7. Global Demand & Opportunities in the mTOR Inhibitor Market

8. Global - Cancer MTOR Inhibitors Clinical Pipeline by Company, Indication & Phase
8.1 Research
8.2 Preclinical
8.3 Phase-I
8.4 Phase-I/II
8.5 Phase-II
8.6 Phase-III

9. Marketed Cancer MTOR Inhibitors Clinical Insight
9.1 Temsirolimus (Torisel)
9.2 Everolimus (Absorb, Affinitor, Affinitor Dispersible, Afinitor, Afinitor Disperz, Certican, Esprit BVS, Promus, Promus Element, Promus Premier, Synergy, Votubia, Xience Prime, Xience V, Xience Xpedition, Xience nano & Zortress)

10. mTOR Inhibitor - Price Analysis by Under Development & Approved Inhibitors
10.1 mTOR Inhibitors Price by Product Under Development
10.1.1 Dactolisib(BEZ 235, NVP-BEZ 235)
10.1.2 Rapamycin
10.1.3 Temsirolimus
10.1.4 PI-103
10.1.5 AZD 8055
10.1.6 Torkinib (pp242)
10.1.7 Ridaforolimus (Deforolimus, MK-8669)
10.1.8 MLN0128 (INK128)
10.1.9 Omipalisib (GSK2126458, GSK458)
10.1.10 Gedatolisib (PF-05212384, PKI-587)
10.1.11 Other Promising mTOR Inhibitors
10.2 Approved & Commercialized Cancer Therapy mTOR Inhibitor Price Analysis
10.2.1 Afinitor/Votubia
10.2.2 Afinitor Disperz - mTOR inhibitor for Rare Pediatric Brain Tumor
10.2.3 Torisel (Temsirolimus)
10.2.4 Evertor - Everolimus by Biocon

11. Market Performance Analysis of mTOR Inhibitors
11.1 Market Performance by Industry
11.1.1 Afinitor by Novartis
11.1.2 Toricel by Pfizer
11.1.3 Evertor by Biocon

12. Comparative Cost Analysis of mTOR Inhibitors with Other Cancer Therapeutics
12.1 Comparative Cost Analysis by other Popular Cancer Therapy Drugs
12.2 Comparative Cost Analysis with Traditional Cancer Therapeutics

13. Regional Analysis of mTOR Inhibitor Market
13.1 North America
13.2 Europe
13.3 Asia Pacific
13.4 Rest of the World

14. Global mTOR Inhibitor Market Dynamics
14.1 Driving Factors of the Global mTOR Inhibitor Market
14.2 Restraining Factors of the Global mTOR Inhibitor Market

15. Future Forecast & Growth Projections of Global mTOR Inhibitors Market

16. Competitive Landscape
16.1 Abraxis BioScience
16.2 Adimab
16.3 Celgene Corporation
16.4 Celator Pharmaceuticals
16.5 Eli Lilly
16.6 Exelixis
16.7 GlaxoSmithKline
16.8 HEC Pharm
16.9 Intellikine
16.10 Novartis
16.11 Oneness Biotech
16.12 PIQUR Therapeutics
16.13 Semafore Pharmaceuticals
16.14 Takeda
16.15 Wyeth

List of Figures
Figure 1-1: mTOR Inhibitors Timeline
Figure 2-1: Normal Functioning of the mTOR Pathway
Figure 3-1: Activators of the mTOR Pathway
Figure 3-2: Global - Cancer MTOR Inhibitors Clinical Pipeline by Phase (%), 2017 till 2022
Figure 3-3: Global - Cancer MTOR Inhibitors Clinical Pipeline by Phase (Number), 2017 till 2022
Figure 3-4: Global - Cancer MTOR Inhibitors Clinical Pipeline by Phase (%), 2017 till 2022
Figure 3-5: Global - Cancer MTOR Inhibitors Clinical Pipeline by Phase (Number), 2017 till 2022
Figure 4-1: mTOR Inhibitors in Action
Figure 5-1: mTOR inhibitors in Breast Cancer
Figure 5-2: The mTOR (PAM) Pathway & Inhibitors of the pathway tested in phase I-III Clinical Trials on Solid Tumors & Breast Cancer
Figure 5-3: Action of Inhibitors under Clinical Development
Figure 6-1: Higher Efficacy of Therapeutics Achieved by using mTOR inhibitor in Combination
Figure 7-1: Global - Breast Cancer Incidence (Per 100,000 females), 2016
Figure 7-2: Global - Kidney Cancer Prevalence (Total Incidence Recorded), 2016
Figure 7-3: Global-Hepatocellular Carcinoma by Region ( per 100, 000),2016
Figure 10-1: Dactolisib- Price Analysis (US$/mg),2017
Figure 10-2: Rapamycin - Price Analysis (US$/mg), 2017
Figure 10-3: Temsirolimus - Price Analysis (US$/gm.), 2017
Figure 10-4: PI-103 Price Analysis (US$/gm.), 2017
Figure 10-5: AZD 8055-Price analysis (US$/mg), 2017
Figure 10-6: Torkinib-Price Analysis (US $/mg), 2017
Figure 10-7: Ridaforolimus- Price Analysis (US$/mg), 2017
Figure 10-8: MLNO 128- Price Analysis (US$/mg), 2017
Figure 10-9: Omipalisib - Price Analysis (US$/mg), 2017
Figure 10-10: Gedatolisib - Price Analysis (US$/mg), 2017
Figure 10-11: Apitolisib (GDC-0980, RG7422) - Price Analysis (US$/mg), 2017
Figure 10-12:  Vistusertib-(AZD2014 (GDC-0980, RG7422) - Price Analysis (US$/mg), 2017
Figure 10-13: Voxtalisib -AZD2014 (GDC-0980, RG7422) - Price Analysis (US$/mg), 2017
Figure 10-14: OSI-27 price analysis (US$/mg), 2017
Figure 10-15: US - Price Analysis of Afinitor by quantity (28 Tablet Packet), 2017
Figure 10-16: Price Analysis- Everolimus Standalone Therapy (US$), 2017
Figure 10-17: Afinitor Disperz - Price Analysis by Quantity (US$), 2017
Figure 10-18: Temsirolimus - Cost Analysis (US$), 2017
Figure 10-19: Cost Analysis - Evertor (Everolimus by Biocon)(US$), 2017
Figure 11-1: Global - Afinitor Sales (US$ Million), 2013-2016
Figure 11-2: Global - Toricel Sales (US$ Million), 2012-2016
Figure 11-3: Global - Evertor Sales (US$ Million), 2012-2016
Figure 12-1: Comparative Cost Analysis - Afinitor (mTOR inhibitor) v/s Other Recommended Therapy for Breast Cancer (US$/Month), 2017
Figure 12-2: Comparative Cost Analysis - Everolimus & Temsirolimus (mTOR inhibitors) v/s Other Recommended Therapy for Kidney Cancer (US$/Month), 2017
Figure 12-3: Comparative Cost Analysis - Average mTOR Inhibitor Therapy v/s Traditional Cancer Therapy Cost
Figure 13-1: Global- mTOR Inhibitor Market by Region (%), 2016 & 2022
Figure 14-1: Global - Driving Factors of the mTOR Inhibitor Market
Figure 14-2: Global - Challenging Factors of the Global mTOR Inhibitor Market
Figure 14-3: Afinitor - Patent Expiration, 2017-2020

List of Tables
Table 3-1: mTOR Overexpression & Related Tumors
Table 11-1: Asia- Leading Manufactures & Suppliers of Everolimus

Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Abraxis BioScience
  • Adimab
  • Celator Pharmaceuticals
  • Celgene Corporation
  • Eli Lilly
  • Exelixis
  • GlaxoSmithKline
  • HEC Pharm
  • Intellikine
  • Novartis
  • Oneness Biotech
  • PIQUR Therapeutics
  • Semafore Pharmaceuticals
  • Takeda
  • Wyeth
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll